Stem Cell Assay Market Overview
The proliferating development of end-users for stem cells research
products like biotechnology and biopharmaceutical industries is set to drive
the Stem Cell Assay Market. The increased introduction of novel products in
different sectors like cell function assays and financing in stem cell-based
therapies is set to propel the growth of the Stem Cell Assay Market during the
forecast period 2022-2027. This represents the Stem Cell Assay Industry
The report: “Stem Cell Assay Market Forecast
(2022-2027)”, by Industry ARC, covers an in-depth analysis of the following
segments of the Stem Cell
Type: Cell Viability And Toxicity Assays, Purification
Assays, Differentiation Assays, Function Assays, Identification Assays,
Proliferation Assays, Cell Apoptosis Assays.
By Cell Type: Adult Stem Cells, Human Embryonic Stem Cells (HESCs).
By Product: Instruments (Flow Cytometer, Cell Imaging Systems, Microelectrode Arrays, Automated Cell Counter), Detection Kits (Immunohistochemistry Kits).
By Application: Regenerative Medicine, Therapy Development, Drug Discovery And Development, Clinical Research.
By End User: Biopharmaceutical And Biotechnology Companies, Research Institutes, Others.
By Geography: North America (the U.S, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Rest of South America) and Rest Of The World (Middle East, Africa).
- Geographically, North America Stem Cell Assay Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of incessant ailments involving the application of cell differentiation and the boost in the population of the elderly in the North American region.
- Stem Cell Assay Market growth is being driven by the assortment of stem cell applications in regenerative medicine, cell differentiation, and their role in the recognition of toxic agents with comparable toxicity. However, the dearth of needed infrastructure in developing economies and the soaring cost of the products are some of the major factors hampering the growth of the Stem Cell Assay Market.
- Stem Cell Assay Market
Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent
players operating in the market will be provided in the Stem Cell Assay Market
Stem Cell Assay Market: Market Share (%) by Region, 2021
Stem Cell Assay Market Segment Analysis – By Assay Type:
The Stem Cell Assay Market
based on assay type can be further segmented into Cell Viability And Toxicity Assays,
Purification Assays, Differentiation Assays, Function Assays, Identification
Assays, Proliferation Assays, and Cell Apoptosis Assays. The Cell Viability And Toxicity Assays Segment held the largest market
share in 2021. This growth is owing to the surging application of Cell Viability And
Toxicity Assays in stem cell research activities. Stem cell differentiation is
assuming importance currently. The role of cell viability assays in deciding
the complete health of cells, making cell culture procedures perfect, and assessing
cell survival after treatment with experimental stimuli or compounds are
further propelling the growth of this segment.
Furthermore, the Cell Apoptosis Assays segment
is estimated to grow with the fastest CAGR of 19.9% during the forecast period
2022-2027 owing to the increased application of cell apoptosis assays in cell biology like
assessing the extent and timing of apoptosis by checking key cellular events in
programmed cell death, like DNA fragmentation in TUNEL, GSH depletion, and
caspase-3 activation and cell differentiation.
Stem Cell Assay Market Segment Analysis – By Application:
The Stem Cell Assay
Market based on the application can be further segmented into Regenerative Medicine, Therapy Development, Drug Discovery And
Development, and Clinical Research. The Regenerative Medicine Segment held the largest market share in 2021. This growth is owing to the expansions
witnessed in the regenerative medicine sector. The capability of stem cells to
self-renew and give rise to consequent generations with varying degrees of
differentiation capacities provides the important possibility for the generation of
tissues that can possibly substitute diseased and damaged areas in the body,
with the nominal hazard of rejection
and side effects. The increasing applications of stem cell differentiation are
further propelling the growth of this segment.
Furthermore, the Drug Discovery And Development segment is estimated to grow with the fastest CAGR of 20.3% during the forecast
period 2022-2027 owing to the proliferating demand for regenerative medicine
and stem cell differentiation in conjunction with the provision of more secure
and affordable medications.
Stem Cell Assay Market Segment Analysis – By Geography:
The Stem Cell Assay
Market based on geography can be further segmented into North America, Europe,
Asia-Pacific, South America, and the Rest of the World. North America (Stem Cell
Assay Market) held the largest share with 35% of the overall market in 2021.
The growth of this region is owing to the proliferating
governmental initiatives backing stem cell-based research in the region. The onset of
progressive technology like stem cell differentiation, the existence of key
players like Biotechne Corporation developing innovative products, and increasing
awareness regarding stem cell assays are propelling the growth of the Stem Cell
Assay Market in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like advancement in the clinical research sector and the surging patient pool in the region. The burgeoning stem cell research resulting in the development of stem cell differentiation and expenditure in the biotechnology sector in conjunction with extensive healthcare infrastructure is fuelling the progress of the Stem Cell Assay Market in the Asia-Pacific region.
Stem Cell Assay Market Drivers
Increased Application Of Stem Cell Research Is Projected To Drive The Growth Of Stem Cell Assay Market:
Research into the reprogramming of somatic cells into pluripotent stem cells was awarded the Nobel Prize in 2012. The lasting significance of this research lies in the utilization of stem cells for regenerative therapies for the interim. However, these cells depict a possible indefinite source of greatly physiologically relevant cells, connected to human primary cells, that may be utilized as drug discovery reagents. The technique of differentiating stem cells into the somatic cell of preference is a lengthy procedure needing careful culturing. The technique normally uses immunofluorescence procedures to decide progenitor cells and terminally differentiated somatic cells. The Agilent BioTek imaging products with liquid handling and Agilent BioTek BioSpa 8 automated CO2 incubator have been planned to allow automated stem cell differentiation. The surging application of stem cell research resulting in automated stem cell differentiation is therefore fuelling the growth of the Stem Cell Assay Market during the forecast period 2022-2027.
Technological Innovations Are Expected To Boost The Demand Of Stem Cell Assays Market:
Technological innovations are driving the growth of the Stem Cell Assay market. Stem Cell Research delves into stem cell differentiation. R&D Systems, a biotech brand, has developed standardized all-in-one Stem Cell Differentiation Kits and media supplements for effective and recreating able stem cell differentiation, involving optimized cocktails of development determinants and tiny molecules. The kits include a marker antibody to confirm stem cell differentiation status including approved, simple, and effortless techniques. The StemXVivo® Differentiation Kits provide researchers the favorable chance to directly differentiate embryonic stem and induced pluripotent stem cells into an assortment of intermediate and terminally differentiated cell types, inclusive of Ectoderm, Mesoderm, Endoderm, Neural Progenitors, Cardiomyocytes, Oligodendrocytes, and Dopaminergic Neurons. These kinds of technological advancements are driving the growth of the Stem Cell Assay Market during the forecast period 2022-2027.
Stem Cell Assay Market Challenges
Challenges Encompassing The Compliance And Variety Of Stem Cell Assays In Hight Throughput Screening (HTS) Are Hampering The Growth Of The Stem Cell Assays Market:
The discrepancy between embryonic stem cell models, like mouse Embryonic Stem Cells (mESCs) versus human Embryonic Stem Cells (ESCs) is demanding. Even with the most recent procedures utilizing nuclear transfer cloning and fusion with ES cells, the hardships persist. The hardships in conjunction with the dearth of ailment applicable models for numerous ailments, propelled the creation of induced pluripotent stem cells (iPSCs) with the eventual goal to resolve the detected basic issues with stem cells. The production of iPSCs from mouse embryonic and adult fibroblasts was performed by introducing four factors: Oct3/4, Sox2, Klf4, and c-Myc6. The establishment of iPSCs permitted numerous to work with ailment applicable models and opened a complete novel avenue in stem cell research. Not only do iPSCs offer an ailment applicable model, but iPSCs are also readily compliant to HTS. However, the addition of the maintenance determinants renders the cell models genomically unstable. Thus, the question arises as to if there is truly a future for small molecules in personalized medicine based on either hESCs or iPSCs. These issues are hampering the growth of the Stem Cell Assays Market.
Stem Cell Assay Market Landscape:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Stem Cell Assay Market. Key companies of this market are:
- Thermo Fisher Scientific
- Promega Corporation
- Bio-Techne Corporation
- GE Healthcare
- Stemcell Technologies
- Cellular Dynamics International (Cdi)
- Bio-Rad Laboratories
- In September 2021, Promega Corporation introduced its OncoMate™ MSI Dx Analysis System (OncoMate™ MSI) in vitro diagnostic (IVD) in the U.S., providing oncologists and pathologists a novel alternative to examine and look for Lynch syndrome in patients with colorectal cancer. OncoMate™ MSI was authorized by the US Food and Drug Administration (FDA) last month as an IVD medical device to conclude on microsatellite instability (MSI) status in colorectal cancer tumors. OncoMate™ MSI is based on Promega technology that has been a gold standard worldwide for the last 15 years for examining MSI status in solid tumors.
- In June 2021, Thermo Fisher Scientific, the global chief in serving science, declared the introduction of a novel CE-IVD-marked COVID-19 test. The TaqPath COVID-19 Fast PCR Combo Kit 2.0. extends Thermo Fisher's menu of greatly precise tests that discover active SARS-CoV-2 contaminations.
- In March 2021,
Thermo Fisher Scientific declared the kick-off of its Applied Biosystems TaqMan
SARS-CoV-2 Mutation Panel, a tailor-made menu of 22 confirmed real-time PCR
assays for recognition of SARS-CoV-2 alterations. These assays allow
surveillance of variants that are bringing about COVID-19 contaminations in particular
regions worldwide and permit laboratories to select which mutations to track.
Therapies Market - Forecast(2021 - 2026)
Report Code: HCR 0384
Stem Cell Banking Market
Report Code: HCR 0459
For more Lifesciences and Healthcare Market reports, please click here